Home › Burkitt Lymphoma › Oklahoma › Oklahoma City
Burkitt Lymphoma clinical trials in Oklahoma City, OK
7 studies for Burkitt Lymphoma are looking for participants at sites in and around Oklahoma City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
RecruitingPhase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
RecruitingPhase 3
- University of Oklahoma Health Sciences Center, Oklahoma City
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
RecruitingPhase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
RecruitingPhase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
RecruitingPhase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
RecruitingPhase 3
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
RecruitingPhase 1/2
- University of Oklahoma Health Sciences Center, Oklahoma City
Burkitt Lymphoma trials in other cities
- Houston, TX21 studies
- Philadelphia, PA16 studies
- Milwaukee, WI16 studies
- Chicago, IL15 studies
- Cincinnati, OH13 studies
- New York City, NY13 studies
- Atlanta, GA12 studies
- Aurora, CO11 studies
- Seattle, WA11 studies
- Durham, NC10 studies
- Kansas City, MO10 studies
- Boston, MA10 studies
Other studies in Oklahoma City
- Non-Small Cell Lung Cancer28 studies
- Ovarian Cancer28 studies
- Endometrial Cancer25 studies
- Colorectal Cancer22 studies
- Prostate Cancer21 studies
- Lung Cancer19 studies
- Breast Cancer17 studies
- Metastatic Cancer16 studies
- Cancer (all types)14 studies
- Acute Myeloid Leukemia14 studies
- Head and Neck Squamous Cell Carcinoma13 studies
- Bladder Cancer11 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.